The latest health and pharmaceuticals industry and company news and analysis from FriedlNews
Page 1/9

Austrian Health and Pharma Headlines

Possible Zika Vaccine Boosts Valneva Share Performance

In hopes of the soon market launch of a vaccine against the Zika virus, investors went for shares of listed biotech firm Valneva, formerly Intercell. The shares of the French firm listed in Vienna had soared 12.4 percent to EUR 3.45 by. Four times more shares than usual had changed hands by the afternoon.

February 4, 2016

Sanochemia Back in Black

The listed Vienna-based pharmaceutical group Sanochemia recorded positive development in the financial year 2014/15. The company managed to achieve a turnaround and returned to profits, after last year’s losses. A new diagnostic agent for bladder cancer is regarded as a cash cow of the future.

January 13, 2016

Wishing you Peace, Joy and Happiness in the New Year

Dear Reader, As the year comes to an end, I wanted to write and thank you for your support. It's the loyalty of readers like you that enables us to provide our service. This year saw us once again reporting on topics related to cross-border activities in business and diplomacy. Our mission remains to inform and to connect Austria's international professionals and expatriates to enable them to be more productive and successful. Whatever 2016 brings, my editorial team and I will continue to bring you the latest in Austrian-international news and insight. I wish you a peaceful and prosperous holiday season and - till next year. Warm regards, Dr. Peter J. Friedl, Editor, FriedlNews

December 23, 2015

FriedlNews wishes Merry Christmas and a Happy New Year from Vienna!

Warmest wishes for the season, and sincere thanks for your loyalty throughout the years! Our service will be closed untill January 11th, 2016. The FriedlNews Team

December 23, 2015

Life Sciences Field is Booming in Vienna

Nine percent revenue growth, five percent increase in the workforce and a large increase in business startups - Vienna as a location for life science businesses is attracting companies at a rate never seen before.

October 14, 2015

Antibiotics Company Nabriva Therapeutics Collects USD 120 Mln from Investors

Viennese biotech firm Nabriva Therapeutics, specialized in antibiotics against resistant bacteria, has collected USD 120 million from investors. The financing process took two tranches, law firm Wolf Theiss, which advised investors together with US firm Cooley, announced on Wednesday.

April 9, 2015

Vamed to Manage First Hospital in China

Vamed is about to establish and manage its first hospital in China - in the provincial capital Haikou on the island of Hainan.

March 30, 2015

Valneva Completes EUR 45 Million Capital Increase

The listed biotechnology company Valneva SE announces the completion of its capital increase with shareholders preferential subscription rights launched on January 12th, 2015. Valneva estimates net proceeds of EUR 42 millions from 18.2 million offered new shares. The new ordinary shares will be traded on Euronext and on the Prime Market segment of the Vienna Stock Exchange. The financing will mainly be used for the acquisition of Crucell Sweden AB and all assets, licenses and privileges related to Dukoral.

February 4, 2015

Pfizer's Agreement To Acquire Baxter’s Portfolio Of Marketed Vaccines Includes Facility in Austria

Pfizer Inc. announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured.

August 1, 2014

Semperit to Realign Rubber Glove Production in Thailand

Listed chemicals group Semperit is realigning its rubber glove production activities in Thailand, i.e. the 50:50 joint venture with the Thai partner Sri Trang which runs a glove plant, Semperit said. The distribution will be realigned as of the turn of 2014 and 2015, while Semperit is also attempting to push through its rights in the JV at court, the company added.

July 18, 2014